MX2021009520A - Composicion oftalmica para el tratamiento de trastornos visuales. - Google Patents

Composicion oftalmica para el tratamiento de trastornos visuales.

Info

Publication number
MX2021009520A
MX2021009520A MX2021009520A MX2021009520A MX2021009520A MX 2021009520 A MX2021009520 A MX 2021009520A MX 2021009520 A MX2021009520 A MX 2021009520A MX 2021009520 A MX2021009520 A MX 2021009520A MX 2021009520 A MX2021009520 A MX 2021009520A
Authority
MX
Mexico
Prior art keywords
visual disorders
ophthalmic composition
lens
treatment
disease
Prior art date
Application number
MX2021009520A
Other languages
English (en)
Inventor
GALINDO Hugo Sergio GARCÍA
Sarmiento Cynthia Cano
OLMOS Ana Guadalupe CASTILLO
MENDOZA Mizraim MORALES
Original Assignee
Foodvica S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foodvica S A De C V filed Critical Foodvica S A De C V
Priority to MX2021009520A priority Critical patent/MX2021009520A/es
Priority to PCT/IB2022/057330 priority patent/WO2023012754A1/es
Priority to EP22852468.2A priority patent/EP4382098A1/en
Priority to CN202280065540.0A priority patent/CN118354765A/zh
Priority to AU2022323657A priority patent/AU2022323657A1/en
Priority to CA3231154A priority patent/CA3231154A1/en
Publication of MX2021009520A publication Critical patent/MX2021009520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención provee una composición oftálmica para el tratamiento y/o prevención de trastornos visuales provocados por cambios en la estructura del cristalino del ojo, particularmente relacionados con la alteración de las proteínas que lo conforman; la composición oftálmica consiste en un compuesto polifenólico en combinación con un terpenoide, o sus sales o formas cristalinas, en cantidades terapéuticamente efectivas, que requiere bajas dosis de compuestos bioactivos para tratar la enfermedad mediante un número reducido de aplicaciones; en específico, la composición oftálmica de la invención puede emplearse para el tratamiento y reversión de trastornos visuales causados por alteraciones en la estructura del cristalino, tales como las cataratas, al ser capaz de revertir la opacidad del cristalino provocada por la enfermedad.
MX2021009520A 2021-08-06 2021-08-06 Composicion oftalmica para el tratamiento de trastornos visuales. MX2021009520A (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2021009520A MX2021009520A (es) 2021-08-06 2021-08-06 Composicion oftalmica para el tratamiento de trastornos visuales.
PCT/IB2022/057330 WO2023012754A1 (es) 2021-08-06 2022-08-05 Composición oftálmica para el tratamiento de trastornos visuales
EP22852468.2A EP4382098A1 (en) 2021-08-06 2022-08-05 Ophthalmic composition for the treatment of visual disorders
CN202280065540.0A CN118354765A (zh) 2021-08-06 2022-08-05 用于治疗视觉障碍的眼用组合物
AU2022323657A AU2022323657A1 (en) 2021-08-06 2022-08-05 Ophthalmic composition for the treatment of visual disorders
CA3231154A CA3231154A1 (en) 2021-08-06 2022-08-05 Ophthalmic composition for the treatment of visual disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2021009520A MX2021009520A (es) 2021-08-06 2021-08-06 Composicion oftalmica para el tratamiento de trastornos visuales.

Publications (1)

Publication Number Publication Date
MX2021009520A true MX2021009520A (es) 2023-02-07

Family

ID=85155533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009520A MX2021009520A (es) 2021-08-06 2021-08-06 Composicion oftalmica para el tratamiento de trastornos visuales.

Country Status (6)

Country Link
EP (1) EP4382098A1 (es)
CN (1) CN118354765A (es)
AU (1) AU2022323657A1 (es)
CA (1) CA3231154A1 (es)
MX (1) MX2021009520A (es)
WO (1) WO2023012754A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176920B (zh) 2008-11-17 2013-09-18 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
WO2016029199A1 (en) 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat vision disorders
CA2993196A1 (en) 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
CN106344587A (zh) 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
CN106511269A (zh) 2016-12-12 2017-03-22 江西中医药大学 一种姜黄素纳米混悬眼用制剂及制备方法
WO2019097434A1 (en) 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders

Also Published As

Publication number Publication date
AU2022323657A1 (en) 2024-03-21
WO2023012754A1 (es) 2023-02-09
CA3231154A1 (en) 2023-02-09
EP4382098A1 (en) 2024-06-12
CN118354765A (zh) 2024-07-16

Similar Documents

Publication Publication Date Title
RU2017144173A (ru) Конструкция линзы с центральной зоной лечения с высокой положительной оптической силой и способ предотвращения и/или замедления прогрессирования миопии
MD3439689T2 (ro) Metode de tratament al hiperlipidemiei cu un inhibitor al ANGPTL8 și un inhibitor al ANGPTL3
ZA202109010B (en) Compounds and methods for the treatment of covid-19
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
NZ704247A (en) Compositions and treatment for eye diseases and disorders
EA201201465A1 (ru) Лекарственные формы хинонов для лечения офтальмических заболеваний
EA201101576A1 (ru) Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
SG10201804008UA (en) Use of complement pathway inhibitors to treat ocular diseases
MX2015012653A (es) Formulaciones oculares para suministro de farmaco al segmento porterior del ojo.
BR112021018591A2 (pt) Compostos e usos dos mesmos
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
BR112022000231A2 (pt) Novos métodos
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
BR112023025789A2 (pt) Nitroxolina para uso no tratamento de neurofibroma cutâneo
MX2019001421A (es) Composiciones de reelina para el tratamiento de trastornos neurologicos.
MX2021009520A (es) Composicion oftalmica para el tratamiento de trastornos visuales.
BR112018072127A2 (pt) inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina
MX2021002017A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
BR112021024835A2 (pt) Tratamento para sinuclenopatias
BR112022020012A2 (pt) Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas